Gentle relief. As nature intended.
Gentle but effective relief from constipation, in a natural high fibre drink.
Order now: Pack Size
Ispagel®Orange-10’s Ispagel®Orange-30’s
RRP* (£)
£2.70 £3.60
Listed Trade Price (£)
£1.65 £2.25
PIP Code 270-6000 281-9118
EAN Code
506001394 4680 506001394 4697
Gentle relief from constipation1 Restores and maintains regularity1 Effective relief of constipation during pregnancy1 Available in pack sizes of 10 and 30 sachets Sugar free**
www.bristol-labsconsumercare.co.uk
PRESCRIBING INFORMATION Product Name: Ispagel® Orange. Composition: Ispaghula husk granules 3.5g per sachet. Please refer to the Summary of Product Characteristics (SmPC) for a full list of excipients. Indication: The treatment of patients requiring a high fibre regime. Please see the SmPC Method of administration: For oral administration as a suspension in water. Granules to be stirred into a glass of 150ml of cold water and taken after effervescence subsides, preferably after meals. Avoid inhalation. The last dose should not be taken before going to sleep. In adults and children over 12 years: - One sachet morning and evening. Elderly: There is no indication that dosage needs to be modified for the elderly. Children aged 12 years and under: Ispagel Orange should not be used in children aged 12 years and under. Other pharmaceutical forms may be more appropriate for administration to this population. Contraindications: - Hypersensitivity to the active substance or any excipients. Intestinal obstruction, faecal impaction, natural or drug-induced reductions in gut motility and colonic atony, such as senile mega-colon. Special warnings and precautions for use: - Allergic sensitisation due to inhalation, leading to hypersensitivity reactions, may occur in individuals with continued occupational contact. Clinical assessment is recommended in individuals at risk, and in cases of proven sensitisation, exposure stopped immediately. Adequate fluid intake should be maintained and the product always taken with at least 150mls of water. The last dose should not be taken immediately before going to sleep. Ispagel Orange should not be given to patients with phenylketonuria. The product contains aspartame, a source of phenylalanine. Interactions with other medicinal products: The product may delay or reduce gastrointestinal absorption of drugs such as cardiac glycosides, coumarin derivatives, lithium, some vitamins (eg B12), and minerals such as calcium, iron or zinc. Pregnancy and lactation: - May be used during pregnancy and lactation. Undesirable effects: Individuals exposed to Ispagel Orange orally, through skin contact or through inhalation, may develop severe hypersensitivity reactions. Attention should be given to individuals routinely handling the product. Flatulence and abdominal distension may occur when taking the product. Overdose: Adequate fluid intact should be maintained. Product Licence Holder: - Bristol Laboratories Limited, Unit 3, Canalside Northbridge Road, Berkhamsted, Hertfordshire, HP4 1EG (PL 17907/0397) Date of Authorisation:- 17-04-2000 Recommended Price: £3.60, 30s sachets packs and £2.70, 10s sachets packs Date of Prescribing Information: 23-08-2016 GSL
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows monitoring of the benefit/risk balance of the medicinal product.
Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Bristol Laboratories Medical Information Department on Telephone: 0044 (0) 1442 200 922
* Recommended retail price
** Contains aspartame, a source of phenylalanine. Reference 1 - Ispagel®Orange SmPc
Date of Preparation: September 2016. Code: UK/ISP/ADV43g/09/2016
Quality • Consistency • Excellence
www.bristol-labs.co.uk
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48